29 April 2020
Visiongain has launched a new pharma report Advanced Therapy Medicinal Products Market Report 2020-2030: Forecasts by Therapy (Cell Therapy (Stem Cell Therapy & Non-stem Cell Therapy), CAR-T Therapy, Gene Therapy, Tissue Engineered Product), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global advanced therapy medicinal products market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that market growth is attributed to groundbreaking new opportunities for the treatment of disease and injury. However, associated rising costs related to these therapies are anticipated to challenge market growth over the forecast period.
To access the data contained in this document please email email@example.com
Visiongain anticipates that the growing ATMP approvals over the next few decades will create financial challenges for public healthcare schemes, insurance companies, and patients. We anticipate that generic versions of ATMP like other branded drugs will make the treatments affordable for the general public.
Additionally, factors such as high production and development cost have led to problems in reimbursements and pricing. For instance, Glybera® (the fourth approved ATMP in the EU) was a gene therapy product for the treatment of lipoprotein lipase deficiency, although it was therapeutically successful it did not set an adequate precedent for advanced medicines due to a lack of foresight regarding the prospective market size, pricing, revenue, and reimbursement models.
ATMPs are evolving quickly because they treat life-threatening diseases with high unmet need, and because of enabling technologies which directly impact on development. These include targeted modification of many different cell types, significant advances in gene delivery capabilities, including a variety of vectors and emerging genome editing technologies (e.g. CRISP-R), innovative regulatory elements (e.g. synthetic promoters) and inducible elements to regulate gene expression (e.g. molecular kill switches to improve safety).
There are 850+ regenerative medicine firms with about 1,000 clinical trials worldwide. As of 31 December 2018, 16 ATMPs were approved by the FDA and 13 ATMPs were allowed by the EMA. Six products have been approved by both agencies. The FDA and EMA have awarded orphan designations to 4 and 8 ATMPs, respectively. These drugs target a variety of disease fields, including progenitor cell transplantation, cancer, and cartilage defects. However, the firms have withdrawn 4 ATMPs approved by the EMA from the sector, claiming commercial reasons for discontinuing their availability. ATMPs have yet to be commercialized successfully. Many things contribute to this: long-term safety remains a potential issue and experience is inadequate Maintenance of efficacy after single administration is a challenge to ensure and measure with a significant impact on risk/benefit assessment.
North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global advanced therapy medicinal products market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Advanced Therapy Medicinal Products Market.
The comprehensive market report features companies such as Celgene Corporation, Gilead Lifesciences, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost, Pharmicell Co., Ltd, Organogenesis Inc., Novartis AG, Bluebird Bio, Inc., Spark Therapeutics, Inc., UniQure N.V., Vericel Corporation among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.